The Pharma and biotech industries are at a pivotal point in their evolution. The companies are facing significant pressure to change with thinning pipelines, skyrocketing R&D costs, calls for lower prices and a greater regulatory burden, these conditions together with the financial crisis have made the work of creating new drugs harder than ever. A time has come for these companies to change the way they manage their R&D activities.
Join the top 20 pharma & biotech and 50 leading regional & global CROs
Experience APRDL 2010 with examples and strategies on innovative R&D, legal and regulatory improvements, as well as new initiatives from the government and industry sectors, including healthcare reform, biologics and others. Take advantage of this unique opportunity to bring back a host of new ideas, user-proven success stories and personal contacts to advance you and your company.
50+ industry leaders across the globe to address:
- Chinese healthcare reform and its implication on drug innovation
- Clinical research in Asia and partnership opportunities
- Commercial success strategies: M&A, licensing, product pipeline optimization
- New cooperation models in Asia for cost cutting and risk sharing
- Excellent outsourcing strategies in Asia: deep analysis on China and India CROs
- The latest biotech trends in Asia and business model from VC perspective
- Latest innovation on leads generation and therapeutics for cancers, CNS, cardiovascular
- Clinical trial innovation: translational medicine and biomarker
More details available at www.aprdl.com
